Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...
(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...
LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV):Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2 ...
Today, GoLocker, New York City's dedicated distribution and access point provider announced a partnership with Toys for Hospitalized Children (TFHC) to transform its network of neighborhood lockers ...
Prescient Therapeutics Limited ( ($AU:PTX) ) has provided an announcement. Prescient Therapeutics Limited has secured Orphan Drug Designation from ...
Zacks Small Cap Research on MSN
AZTR: ATR-01 Data Presented
AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported third quarter 2025 results in a November 12th press release and provided a business update. Since our previous quarterly ...
Clascoterone cream 1% reduced facial sebum for adolescents and adults with acne vulgaris, resulting in a decrease in oily ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback